Generic drug maker Mylan has struck a deal with pharma companies Shionogi and Andrx to resolve a patent dispute over their diabetes drug Fortamet.
Janssen Products, a subsidiary of Johnson & Johnson, has sued Indian pharmaceutical company Hetero Drugs for applying to market a generic version of its HIV treatment Prezista.
ViiV Healthcare, a public health joint venture between GlaxoSmithKline, Shionogi and Pfizer, has signed up to the Medicines Patent Pool (MPP) to provide greater access to affordable AIDS treatments in developing countries.
The US Food and Drug Administration has approved two generic versions of Reckitt Benckiser’s heroin replacement tablet Suboxone – despite Reckitt’s claims that the product is unsafe.
In a report published by Thomson Reuters on February 20, the BRICK nations were shown to be filing almost as many patents as the G7 nations in 2011.
The US Court of Appeals for the Federal Circuit has affirmed a 2012 ruling that AstraZeneca’s patent for antipsychotic drug Seroquel XR is valid and has been infringed by companies selling competing generics.
Israeli company Teva Pharmaceuticals could be forced to pay more than $2 billion in damages for selling a generic version of Nycomed and Pfizer’s heartburn reliever Protonix before the drug’s patent exclusivity expired in the US.
A US judge has declared pharmaceutical company Bristol-Myers Squibb’s patent covering its hepatitis B treatment Baraclude obvious and invalid.
India’s Patent Office has revoked pharmaceutical company Sugen and licensee Pfizer’s patent for the cancer drug Sutent, agreeing with Indian drugs maker Cipla that it lacks inventive step.
The Mexican Senate has published a bill which, if adopted, will reduce the life term of medicine patents in Mexico by up to one year.